Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Changes in the IgG glycome associated with inflammatory bowel disease (CROSBI ID 638468)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Keser, Toma ; Trbojević Akmačić, Irena ; Ventham, Nicholas T ; Theodoratou, Evropi ; Vučković, Frano ; Kennedy, Nicholas A ; Nimmo, Elaine R ; Kalla, Rahul ; Drummond, Hazel ; Štambuk, Jerko et al. Changes in the IgG glycome associated with inflammatory bowel disease // Glycoconjugate journal / Vliegenthart, J.F.G. (ur.). 2015. str. 265-265

Podaci o odgovornosti

Keser, Toma ; Trbojević Akmačić, Irena ; Ventham, Nicholas T ; Theodoratou, Evropi ; Vučković, Frano ; Kennedy, Nicholas A ; Nimmo, Elaine R ; Kalla, Rahul ; Drummond, Hazel ; Štambuk, Jerko ; Campbell, Harry ; Hedin, Charlotte ; D'Amato, Mauro ; Halfvarsson, Jonas ; Satsangi, Jack ; Lauc, Gordan

engleski

Changes in the IgG glycome associated with inflammatory bowel disease

Glycobiology is an underexplored research area in inflammatory bowel disease (IBD), and glycans are relevant to many aetiological mechanisms described in IBD. Alterations in N- glycans attached to the IgG Fc fragment can affect molecular structure and immunological function. Recent genome-wide association studies reveal pleiotropy between IBD and IgG glycosylation. We conducted two studies to better understand changes in the IgG glycome associated with IBD. In the first study we analyzed IgG glycans in 507 patients with ulcerative colitis (UC), 287 patients with Crohn’s disease (CD) and 320 controls. Statistically significant differences in IgG glycome composition between patients with UC, or CD, compared to controls, were observed. Both UC and CD were associated with significantly decreased IgG galactosylation (digalactosylation, UC Odds ratio [OR]=0.71, 95% confidence interval[CI] 0.5-0.9, p=0.01, CD OR=0.41, CI 0.3-0.6, p=1.4x10-9) and significant decrease in the proportion of sialylated structures in CD (OR=0.46, CI 0.3- 0.6, p=8.4x10-8). Logistic regression models incorporating measured IgG glycan traits were able to distinguish UC and CD from controls (UC p=2.13x10-6, CD p=2.20x10-16), with receiver operator characteristic curves demonstrating better performance of the CD model (Area under curve[AUC]=0.77) over the UC model (AUC=0.72) (p=0.026). The observed differences indicate significantly increased inflammatory potential of IgG in IBD. In the second study we analyzed IgG glycans in 87 twin pairs discordant for IBD, 16 twin pairs with IBD and 103 healthy controls. The results indicate that healthy twins are more similar to healthy controls than to their diseased twins.

Inflammatory bowel disease; Glycomics; IgG glycans; Ulcerative colitis; Crohn’s disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

265-265.

2015.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Glycoconjugate journal

Vliegenthart, J.F.G.

New York (NY): Springer

0282-0080

Podaci o skupu

GLYCO 23 XXIII International Symposium on Glycoconjugates

poster

15.09.2015-20.09.2015

Split, Hrvatska

Povezanost rada

Biologija

Indeksiranost